These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35390793)

  • 21. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
    Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
    J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Br J Haematol; 2020 Jan; 188(2):207-223. PubMed ID: 31566728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should immunologic strategies be incorporated into frontline ALL therapy?
    Rank CU; Stock W
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
    Bumma N; Papadantonakis N; Advani AS
    Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
    Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
    Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
    Advani A
    Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody based therapy in relapsed acute lymphoblastic leukemia.
    Jammal N; Chew S; Jabbour E; Kantarjian H
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Therapies in Acute Lymphoblastic Leukemia.
    Phelan KW; Advani AS
    Curr Hematol Malig Rep; 2018 Aug; 13(4):289-299. PubMed ID: 30078158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [ALL in adult patients: Contribution and limits of pediatric management].
    Rabian F; Boissel N
    Bull Cancer; 2021 Feb; 108(2):187-197. PubMed ID: 32981690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.
    Franca R; Favretto D; Granzotto M; Decorti G; Rabusin M; Stocco G
    Curr Med Chem; 2017; 24(11):1050-1065. PubMed ID: 28088906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia.
    Viardot A; Sala E
    Expert Opin Investig Drugs; 2021 Jul; 30(7):773-784. PubMed ID: 33998346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
    DuVall AS; Wesevich A; Larson RA
    Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.
    Dias A; Kenderian SJ; Westin GF; Litzow MR
    Curr Hematol Malig Rep; 2016 Aug; 11(4):253-64. PubMed ID: 27101015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric acute lymphoblastic leukemia.
    Inaba H; Mullighan CG
    Haematologica; 2020 Nov; 105(11):2524-2539. PubMed ID: 33054110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.
    Frey NV; Porter DL
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):567-572. PubMed ID: 27913530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
    Litzow MR
    Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.